Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide

British Journal of Haematology

Volumn 148, Issue 2, 2010, Pages 226-234

  Dean, Robert M ^a   Pohlman, Brad ^a   Sweetenham, John W ^a   Sobecks, Ronald M ^a   Kalaycio, Matt E ^a   Smith, Stephen D ^a   Copelan, Edward A ^a   Andresen, Steven ^a   Rybicki, Lisa A ^b   Curtis, Julie ^a   Bolwell, Brian J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autologous stem cell transplantation; Mucositis; Non Hodgkin lymphoma; Relapse; Survival

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACCIDENTAL INJURY; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; ENGRAFTMENT SYNDROME; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HOMICIDE; HUMAN; INCIDENCE; INFECTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; SUICIDE; T CELL LYMPHOMA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 72649087456     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07940.x     Document Type: Article

References (37)

1. Aggarwal, C., Gupta, S., Vaughan, W.P., Saylors, G.B., Salzman, D.E., Katz, R.O., Nance, A.G., Tilden, A.B. Carabasi, M.H. (2006) Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biology of Blood and Marrow Transplantation, 12, 770 777.
2. Andersson, B.S., Madden, T., Tran, H.T., Hu, W.W., Blume, K.G., Chow, D.S., Champlin, R.E. Vaughan, W.P. (2000) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biology of Blood and Marrow Transplantation, 6, 548 554.
3. Andersson, B.S., Thall, P.F., Madden, T., Couriel, D., Wang, X., Tran, H.T., Anderlini, P., de Lima, M., Gajewski, J. Champlin, R.E. (2002) Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biology of Blood and Marrow Transplantation, 8, 477 485.
4. Beri, R., Chunduri, S., Sweiss, K., Peace, D.J., Mactal-Haaf, C., Dobogai, L.C., Shord, S., Quigley, J.G., Chen, Y.H., Mahmud, N. Rondelli, D. (2009) Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplantation, doi :.
5. Bhagwatwar, H.P., Phadungpojna, S., Chow, D.S. Andersson, B.S. (1996) Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemotherapy and Pharmacology, 37, 401 408.
6. Bolwell, B.J., Pohlman, B., Andresen, S., Kalaycio, M., Goormastic, M., Wise, K., Wakeling, A., Dannley, R. Overmoyer, B. (1998) Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplantation, 21, 369 373.
7. Bolwell, B., Kalaycio, M., Sobecks, R., Andresen, S., McBee, M., Kuczkowski, L., Rybicki, L. Pohlman, B. (2002) Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplantation, 29, 673 679.
8. Clopes, A., Sureda, A., Sierra, J., Queralto, J.M., Broto, A., Farre, R., Moreno, E., Brunet, S., Martino, R. Mangues, M.A. (2006) Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. European Journal of Haematology, 77, 1 6.
9. Copelan, E.A., Penza, S.L., Pohlman, B., Avalos, B.R., Goormastic, M., Andresen, S.W., Kalaycio, M., Bechtel, T.P., Scholl, M.D., Elder, P.J., Ezzone, S.A., O'Donnell, L.C., Tighe, M.B., Risley, G.L., Young, D.C. Bolwell, B.J. (2000) Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation, 25, 1243 1248.
10. Copelan, E.A., Bechtel, T.P., Avalos, B.R., Elder, P.J., Ezzone, S.A., Scholl, M.D. Penza, S.L. (2001) Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplantation, 27, 1121 1124.
11. Dean, R., Pohlman, B., Sweetenham, J.W., Sobecks, R., Kalaycio, M., Andresen, S., Rybicki, L., Lowe, C., Brown, S., Curtis, J. Bolwell, B. (2006) The use of intravenous compared with oral busulfan in high-dose chemotherapy and autologous stem cell transplantation (ASCT) for lymphoma is associated with improved relapse-free survival. Blood, 108, 868a (Abstract 3050).
12. Fanning, S.R., Rybicki, L., Kalaycio, M., Andresen, S., Kuczkowski, E., Pohlman, B., Sobecks, R., Sweetenham, J. Bolwell, B. (2006) Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. British Journal of Haematology, 135, 374 381.
13. Field, T., Perkins, J., Alsina, M., Ayala, E., Fancher, K., Janssen, W., Perez, L., Sullivan, D., Tate, C. Anasetti, C. (2005) Targeted intravenous busulfan combined with fludarabine (tBuFlu) as conditioning prior to allogeneic peripheral blood stem cell transplant: early results of low treatment related mortality. Blood, 106, 500a (Abstract 1759).
14. Gaziev, J., Spitaleri, L., Mozzi, A., Nguyen, L., Puozzo, C., Perrone, M., Casella, M., Polchi, Sr., P., Sodani, P., Redaelli, G., Simone, M., Montuoro, A., Marziali, M., Isgro, A., Gallucci, C., Alfieri, C., Paciaroni, K., Roveda, A., De Angelis, G. Lucarelli, G. (2008) Clinical outcomes and pharmacokinetics of targeted intravenous busulfan in children receiving stem cell transplantation for thalassemia. Blood, 112, 408a (Abstract 1117).
15. Grochow, L.B. (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Seminars in Oncology, 20, 18 25 quiz 26.
16. Grochow, L.B., Jones, R.J., Brundrett, R.B., Braine, H.G., Chen, T.L., Saral, R., Santos, G.W. Colvin, O.M. (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemotherapy and Pharmacology, 25, 55 61.
17. Hanel, M., Kroger, N., Sonnenberg, S., Bornhauser, M., Kruger, W., Kroschinsky, F., Hanel, A., Metzner, B., Birkmann, J., Schmid, B., Hoffknecht, M.M., Fiedler, F., Ehninger, G. Zander, A.R. (2002) Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Annals of Hematology, 81, 96 102.
18. Hassan, M., Oberg, G., Bjorkholm, M., Wallin, I. Lindgren, M. (1993) Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemotherapy and Pharmacology, 33, 181 186.
19. Hassan, M., Ljungman, P., Ringden, O., Hassan, Z., Oberg, G., Nilsson, C., Bekassy, A., Bielenstein, M., Abdel-Rehim, M., Georen, S. Astner, L. (2000) The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplantation, 25, 915 924.
20. Jones, R.J. Santos, G.W. (1989) New conditioning regimens for high risk marrow transplants. Bone Marrow Transplantation, 4 (Suppl. 4 15 17.
21. Kalaycio, M., Pohlman, B., Kuczkowski, E., Rybicki, L., Andresen, S., Sobecks, R. Bolwell, B. (2006) High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant. Clinical Transplantation, 20, 783 787.
22. Kashyap, A., Wingard, J., Cagnoni, P., Roy, J., Tarantolo, S., Hu, W., Blume, K., Niland, J., Palmer, J.M., Vaughan, W., Fernandez, H., Champlin, R., Forman, S. Andersson, B.S. (2002) Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biology of Blood and Marrow Transplantation, 8, 493 500.
23. Kim, J.G., Sohn, S.K., Chae, Y.S., Yang, D.H., Lee, J.J., Kim, H.J., Shin, H.J., Jung, J.S., Kim, W.S., Kim, D.H., Suh, C., Kim, S.J., Eom, H.S. Bae, S.H. (2007) Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v.Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation, 40, 919 924.
24. Lazarus, H.M., Carreras, J., Boudreau, C., Loberiza, Jr., F.R., Armitage, J.O., Bolwell, B.J., Freytes, C.O., Gale, R.P., Gibson, J., Hale, G.A., Inwards, D.J., LeMaistre, C.F., Maharaj, D., Marks, D.I., Miller, A.M., Pavlovsky, S., Schouten, H.C., van Besien, K., Vose, J.M., Bitran, J.D., Khouri, I.F., McCarthy, P.L., Yu, H., Rowlings, P., Serna, D.S., Horowitz, M.M. Rizzo, J.D. (2008) Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biology of Blood and Marrow Transplantation, 14, 1323 1333.
25. Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. Goldstone, A.H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 13, 588 595.
26. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y. Harousseau, J.L. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. [see comments]. New England Journal of Medicine, 333, 1540 1545.
27. Santos, G.W., Tutschka, P.J., Brookmeyer, R., Saral, R., Beschorner, W.E., Bias, W.B., Braine, H.G., Burns, W.H., Elfenbein, G.J., Kaizer, H., Sensenbrenner, L.L., Stuart, R.K. Yeager, A.M. (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New England Journal of Medicine, 309, 1347 1353.
28. Santos, E.C., Sessions, J., Hutcherson, D., Flowers, C., Langston, A. Waller, E.K. (2007) Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation - a similar experience. Biology of Blood and Marrow Transplantation, 13, 746 747.
29. Slattery, J.T. (2003) Re: intravenous versus oral busulfan - perhaps not as different as suggested. Biology of Blood and Marrow Transplantation, 9, 282 284.
30. Slattery, J.T., Sanders, J.E., Buckner, C.D., Schaffer, R.L., Lambert, K.W., Langer, F.P., Anasetti, C., Bensinger, W.I., Fisher, L.D., Appelbaum, F.R. Hansen, J.A. (1995) Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplantation, 16, 31 42.
31. Slattery, J.T., Kalhorn, T.F., McDonald, G.B., Lambert, K., Buckner, C.D., Bensinger, W.I., Anasetti, C. Appelbaum, F.R. (1996) Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. Journal of Clinical Oncology, 14, 1484 1494.
32. Slattery, J.T., Clift, R.A., Buckner, C.D., Radich, J., Storer, B., Bensinger, W.I., Soll, E., Anasetti, C., Bowden, R., Bryant, E., Chauncey, T., Deeg, H.J., Doney, K.C., Flowers, M., Gooley, T., Hansen, J.A., Martin, P.J., McDonald, G.B., Nash, R., Petersdorf, E.W., Sanders, J.E., Schoch, G., Stewart, P., Storb, R., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P. Appelbaum, F.R. (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood, 89, 3055 3060.
33. Sonis, S.T. (2004) Oral mucositis in cancer therapy. The Journal of Supportive Oncology, 2, 3 8.
34. Stiff, P.J., Dahlberg, S., Forman, S.J., McCall, A.R., Horning, S.J., Nademanee, A.P., Blume, K.G., LeBlanc, M. Fisher, R.I. (1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - a Southwest Oncology Group trial. Journal of Clinical Oncology, 16, 48 55.
35. Tran, H., Petropoulos, D., Worth, L., Mullen, C.A., Madden, T., Andersson, B., Choroszy, M., Nguyen, J., Webb, S.K. Chan, K.W. (2004) Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 10, 805 812.
36. Wadehra, N., Farag, S., Bolwell, B., Elder, P., Penza, S., Kalaycio, M., Avalos, B., Pohlman, B., Marcucci, G., Sobecks, R., Lin, T., Andresen, S. Copelan, E. (2006) Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biology of Blood and Marrow Transplantation, 12, 1343 1349.
37. Wingard, J.R., Mellits, E.D., Sostrin, M.B., Chen, D.Y., Burns, W.H., Santos, G.W., Vriesendorp, H.M., Beschorner, W.E. Saral, R. (1988) Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine, 67, 175 186.